Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
IMMUNE EFFECTOR CELL THERAPIES WITH ENHANCED EFFICACY
Document Type and Number:
WIPO Patent Application WO/2018/059549
Kind Code:
A1
Abstract:
Provided herein is the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., a disease associated with expression of a tumor antigen.

Inventors:
MOTZ GREGORY (US)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
Application Number:
PCT/CN2017/104422
Publication Date:
April 05, 2018
Filing Date:
September 29, 2017
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NOVARTIS AG (CH)
UNIV PENNSYLVANIA (US)
MOTZ GREGORY (US)
MAVRAKIAS KONSTANTINOS JOHN (US)
LIU JINBIAO (CN)
LIU LEI (CN)
ZHENG QIANGANG (CN)
XUN GUOLIANG (CN)
XIAO QITAO (CN)
International Classes:
C07D401/04; A61K31/33; A61P35/00; C07D209/14
Domestic Patent References:
WO2017149463A12017-09-08
WO2017114497A12017-07-06
WO2015134973A12015-09-11
WO2016029262A12016-03-03
WO2014205511A12014-12-31
WO2013033688A12013-03-07
WO2005044996A22005-05-19
WO2016014565A22016-01-28
Foreign References:
US20160152595A12016-06-02
Other References:
See also references of EP 3523290A4
Attorney, Agent or Firm:
ZHONGZI LAW OFFICE (CN)
Download PDF: